Which drug is marketed under the brand Xeljanz?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $9.99Unlock all

Enhance your dermatological knowledge with the Dermatology Week 1 Exam. Engage with multiple choice questions that provide insights and detailed explanations to gear you up for testing success. Prepare effectively for your exam!

Multiple Choice

Which drug is marketed under the brand Xeljanz?

Explanation:
Xeljanz refers to tofacitinib, a small-molecule JAK inhibitor used to treat inflammatory conditions by dampening cytokine signaling. This brand-name mapping is why tofacitinib is the correct choice here. Other drugs listed have different brand names: Upadacitinib is Rinvoq, Baricitinib is Olumiant, and Abatacept is Orencia. Abatacept is not a JAK inhibitor at all; it’s a CTLA-4Ig fusion protein that blocks T-cell activation. So the drug marketed under Xeljanz is tofacitinib.

Xeljanz refers to tofacitinib, a small-molecule JAK inhibitor used to treat inflammatory conditions by dampening cytokine signaling. This brand-name mapping is why tofacitinib is the correct choice here. Other drugs listed have different brand names: Upadacitinib is Rinvoq, Baricitinib is Olumiant, and Abatacept is Orencia. Abatacept is not a JAK inhibitor at all; it’s a CTLA-4Ig fusion protein that blocks T-cell activation. So the drug marketed under Xeljanz is tofacitinib.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy